Galena Biopharma Inc (GALE) is Reiterated by FBR Capital to Outperform, Lowers Price Target to $ 2

Galena Biopharma Inc (GALE) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 2 from a previous price target of $5 . FBR Capital advised their investors in a research report released on Jul 22, 2016.

Many Wall Street Analysts have commented on Galena Biopharma Inc. Shares were Reiterated by Maxim Group on Jul 11, 2016 to “Buy” and Lowered the Price Target to $ 2 from a previous price target of $4 .Galena Biopharma Inc was Downgraded by Raymond James to ” Mkt Perform” on Jun 29, 2016.

On the company’s financial health, Galena Biopharma Inc reported $-0.07 EPS for the quarter, based on the information available during the earnings call on May 10, 2016. Analyst had a consensus estimate of $-0.07.During the same quarter in the previous year, the company posted $-0.08 EPS.

Galena Biopharma Inc opened for trading at $0.38 and hit $0.49 on the upside on Wednesday, eventually ending the session at $0.4855, with a gain of 27.39% or 0.1044 points. The heightened volatility saw the trading volume jump to 2,14,62,539 shares. Company has a market cap of $88 M.

In a different news, on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at $2.18 per share price.

Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Galena Biopharma Inc

Leave a Reply

Galena Biopharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Galena Biopharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.